CIBC Asset Management
MDGL icon

CIBC Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

CIBC Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Sell
709
-107
-13% -$54.8K ﹤0.01% 932
2026
Q1 		$427K Hold
816
– – ﹤0.01% 840
2025
Q4 		$475K Buy
816
+190
+30% +$97K ﹤0.01% 813
2025
Q3 		$287K Buy
+626
New +$234K ﹤0.01% 949
2025
Q2 		– Sell
-626
Closed -$207K – 1236
2025
Q1 		$207K Buy
+626
New +$206K ﹤0.01% 1060

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CIBC Asset Management's MDGL Position: Q2 2026 in Review

CIBC Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 13% in Q2 2026, selling an estimated $54.8K and leaving 709 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

CIBC Asset Management first reported a position in MDGL in Q1 2025 and has held it in 5 quarters since. The position peaked at $475K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • CIBC Asset Management held 709 shares of Madrigal Pharmaceuticals worth $381K as of Q2 2026.
  • CIBC Asset Management sold 107 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $54.8K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #932 holding.
  • CIBC Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • CIBC Asset Management's Madrigal Pharmaceuticals position peaked at $475K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.